Nasdaq

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase ...
Nasdaq

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, ...
Donga Science

MSD’s anticancer drug Keytruda faces patent expiry as it reshapes immunotherapy

The domestic patent for Keytruda, the world’s top-selling medicine by annual sales, is scheduled to expire in 2028. A fierce ...
Cure Today

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...
Medical News Today

Opdivo vs. Keytruda

Side effects of Opdivo vs. Keytruda Both Opdivo and Keytruda treat certain types of cancer. They also belong to the same medication class. Because of this, these drugs can cause some of the same side ...
Cure Today

FDA Priority Review for Padcev Combo in Bladder Cancer

FDA Priority Review targets perioperative enfortumab vedotin plus pembrolizumab use in MIBC irrespective of cisplatin eligibility, with an August 17, 2026 decision date. EV-304/KEYNOTE-B15 showed a 47 ...